Trial reportPharmaceutical research2007
An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects.
Trial report in Pharmaceutical research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Prophylactic effect of erythropoietin injection to prevent acute mountain sickness: an open-label randomized controlled trial.Journal of Korean medical science · 2014Trial
- Early effects of erythropoietin on serum hepcidin and serum iron bioavailability in healthy volunteers.European journal of applied physiology · 2012Trial
- Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects.Clinical pharmacokinetics · 2009Trial
- Altitude and Erythropoietin: Comparative Evaluation of Their Impact on Key Parameters of the Athlete Biological Passport: A Review.Frontiers in sports and active living · 2022Review
- Application of Reticulocyte-Based Estimation of Red Blood Cell Lifespan in Anemia Management of End-Stage Renal Disease Patients.The AAPS journal · 2020Observational
- Nitric oxide synthetic pathway and cGMP levels are altered in red blood cells from end-stage renal disease patients.Molecular and cellular biochemistry · 2016Article
- Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations.Journal of pharmacokinetics and pharmacodynamics · 2014Article
- Lifespan based indirect response models.Journal of pharmacokinetics and pharmacodynamics · 2012Review
- Receptor-based dosing optimization of erythropoietin in juvenile sheep after phlebotomy.Drug metabolism and disposition: the biological fate of chemicals · 2011Article
- Development of an erythropoietin prescription simulator to improve abilities for the prescription of erythropoietin stimulating agents: is it feasible?BMC nephrology · 2011Article
- Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin.Haematologica · 2010Article
- Pharmacodynamic modeling of the effect of changes in the environment on cellular lifespan and cellular response.Journal of pharmacokinetics and pharmacodynamics · 2008Article
- Modeling time variant distributions of cellular lifespans: increases in circulating reticulocyte lifespans following double phlebotomies in sheep.Journal of pharmacokinetics and pharmacodynamics · 2008Article
- Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.Journal of pharmacokinetics and pharmacodynamics · 2008Article
- Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects.Clinical pharmacokinetics · 2008Article
- Radiation sensitivity and genomic instability in the hematopoietic system: Frequencies of micronucleated reticulocytes in whole-body X-irradiated BALB/c and C57BL/6 mice.Cancer science · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
Abstract
purposeAn empirical pharmacodynamic model was developed to assess the effect of recombinant human erythropoietin (rHu-EPO) treatment on the reticulocyte production rate and lifespan distribution. MATERIALS AND
methodsSingle doses of rHu-EPO at levels 20, 40, 60, 90, 120, and 160 kIU were administered to healthy volunteers (n = 8 per dose level). Erythropoietin plasma concentrations as well as hematologic responses were measured up to 42 days. The hematological data were used to determine explicit relationships between reticulocyte and red blood cell counts (RBC) and the reticulocytes' production rate and lifespan distribution.
resultsThe parameter estimates obtained by simultaneous fitting of the model to the reticulocyte and RBC data revealed that rHu-EPO transiently increased the reticulocyte lifespan from the baseline value of 1.7 days to 3.4 days and the effect lasted for 8.3 days. The dose dependent increase in the reticulocyte production had the maximal value of 77.5 10(9) cells/l/day and was followed by a rebound that was less than 9% of the baseline value. Both reticulocyte and RBC responses were preceded by a dose-independent lag time of 1.7 days.
conclusionsThe effect of rHu-EPO on the reticulocyte production rate and lifespan distribution was characterized. The results of the present study can be further utilized in building more mechanistic pharmacodynamic models of rHu-EPO stimulatory effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.